What is SymbioCellTech?
SymbioCellTech is at the forefront of developing innovative therapies for Type 1 Diabetes, with a primary objective to eliminate the reliance on daily insulin injections and mitigate associated complications. The company's flagship product, Neo-Islets, represents a next-generation therapeutic approach that bypasses the need for immunosuppressive agents. Targeting the 16 million individuals in the United States affected by Type 1 Diabetes, SymbioCellTech's commitment to advancing patient care was recognized with the American Diabetes Association's Innovation Challenge Award in 2024.
How much funding has SymbioCellTech raised?
SymbioCellTech has raised a total of $4.5M across 2 funding rounds:
Private Equity
$2.6M
Private Equity
$1.9M
Private Equity (2014): $2.6M, investors not publicly disclosed
Private Equity (2016): $1.9M, investors not publicly disclosed
What's next for SymbioCellTech?
The substantial enterprise-level funding and recent strategic investment position SymbioCellTech for accelerated growth and the scaling of its Neo-Islets technology. This capital infusion is expected to fuel further research and development, clinical trials, and market penetration efforts. The company's focus on a non-immunosuppressive solution for Type 1 Diabetes indicates a strategic move to address a critical unmet need in the diabetes care market, potentially leading to significant advancements in patient outcomes and a strong competitive advantage.
See full SymbioCellTech company page
